Article
Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice.
In vivo (Athens, Greece) - 1 Jan 2000
Katsuya Yuki, Miyake Kentaro, Higuchi Takashi, Oshiro Hiromichi, Sugisawa Norihiko, Singh Shree Ram, Goto Yasushi, Zhao Ming, Hoffman Robert M
Abstract excerpt
BACKGROUND/AIM: Brain metastases are found in approximately 30% of patients with epidermal-growth-factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We compared the efficacy of two EGFR-tyrosine kinase inhibitors (TKIs), erlotinib and osimertinib on a PC-9-GFP EGFR mutant NSCLC growing in the brain of nude mice. MATERIALS AND METHODS: The brain metastasis models were randomized into five groups and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.